A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Status:
Completed
Trial end date:
2019-06-19
Target enrollment:
Participant gender:
Summary
Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with
advanced solid tumors and varying degrees of renal impairment.